Drug hope for brain diseases promulgated

SYDNEY: An experimental drug that has been able to wake up people from dementia will now be tested with the hope of clearing Parkinson’s disease brain fog.

Anavex 2-73 was originally developed as a potential treatment for Alzheimer’s but, after promising results with that disease, Melbourne patients will be among the first in the world to test the tablet’s wider neuroprotective effects.

Aside from physical symptoms such as tremors and muscle stiffness, Parkinson’s disease is associated with memory, concentration and decision-making problems.

Lead researcher Steve Macfarlane, from HammondCare Dementia Centre, said experiments in mice had shown that the drug could restore the function of damaged nerve cells and improve motor function.

It is believed the drug works not only by preventing the build-up of abnormal proteins but by addressing other damaging processes in the brain.

The trial, which is being partly funded by the Michael J. Fox Foundation, will recruit, 120 patients worldwide.